Jumpstart Joins Bionow
News Sep 23, 2014
Jumpstart, the leading UK research and development (R&D) tax relief specialist, has joined Bionow, the body which supports business growth, competitiveness and innovation within the biomedical and life science sectors across Northern England.
One of its first activities will be to attend the BioCap conference in Manchester on September 29th, an event which brings together international investors, companies who are seeking finance and those who have a track record of raising finance.
Jumpstart Managing Director Brian Williamson will be taking part in a panel discussion at the conference on alternative sources of funding for innovative companies.
Jumpstart's membership of Bionow will be significantly beneficial to both parties. The company has helped clients recover more than £43 million from HMRC and will provide information to Bionow which is relevant to life science businesses in the area of tax relief.
Bionow's membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms. Its membership base includes start-ups and early stage firms as well as established growth-oriented companies.
Simon Fisk, who, along with David Milnes, is one of Jumpstart’s business analysts for the North-East of England, said: "This is a very important development. There are many life science companies in the area, including well-known success stories such as AstraZeneca.
"Jumpstart can bring a great deal to the table at Bionow as well as finding out more about the specific issues that growing companies face in the sector at different stages of their development."
Jumpstart will exhibit at BioInfect 2014, a major one-day conference at Alderley Park, Cheshire, on November 4th looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance.
The company will also be represented at the Bionow Annual Awards Dinner at Mere, in Cheshire on November 27th.
Brian Williamson said: "Our involvement with some of the most exciting life science companies in Britain will help us to understand how we can best help the sector to achieve important new funding streams."
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE